Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Outcomes of second hematopoietic stem cell transplantation for relapsed myelodysplastic syndrome: An updated analysis of Japanese nationwide transplant registry

Kamma Shiraishi, Yoshimitsu Shimomura, Hiroki Hosoi et al. Nov 03, 2025 pp. 4259-4259 10.1182/blood-2025-4259

Abstract Background Myelodysplastic syndrome (MDS) is associated with dismal outcomes after relapse following hematopoietic stem cell transp...

Beyond overall declines: Unequal trends in multiple myeloma mortality across racial and demographic subgroups in the United States from 2018-2023

Mandeepsinh Vashi, Hardik Jain, Khushbu Patel et al. Nov 03, 2025 pp. 7553-7553 10.1182/blood-2025-7553

Abstract Background: Multiple myeloma (MM) mortality has declined in the United States, yet racial and demographic disparities persist. Cont...

A first-in-human study of stx-0712, a CCR2+ cytotoxicity targeting chimera (CyTAC™) in patients with chronic myelomonocytic leukemia (CMML) and Acute Myeloid Leukemia (AML)

Guillermo Montalban-Bravo, Courtney DiNardo, Peter Greenberg et al. Nov 03, 2025 pp. 3874-3874 10.1182/blood-2025-3874

Abstract Background and Significance: CMML is a myeloid neoplasm characterized by hematopoietic stem and progenitor cell (HSPCs) monocytic bi...

Quality of life and organization of care in patients with chronic myeloid leukemia (CML) within the lombardy hematologic network (REL): The CML-OPERAP study

Giacomo Mossini, Federica Colombo, Nicola Orofino et al. Nov 03, 2025 pp. 2827-2827 10.1182/blood-2025-2827

Abstract Background Chronic Myeloid Leukemia (CML) accounts for 10-15% of adult leukemias by incidence, with a rising prevalence of ~3/10000...

Complete donor chimerism following deceased-donor liver transplant in an adolescent with hepatitis-associated severe aplastic anemia

Alison Bertuch, Minoti Vather, Elizabeth Moulton et al. Nov 03, 2025 pp. 3209-3209 10.1182/blood-2025-3209

Abstract Aplastic anemia (AA) develops in up to 28% percent of children with indeterminate acute liver failure (ALF), often within two month...

Characterizing the biological function FOXO3 and its role as a predictive biomarker in HTLV-1 related adult T-cell leukemia-lymphoma

Georgios Pongas, Ngoc Toomey, Juan Carlos Ramos Nov 03, 2025 pp. 3546-3546 10.1182/blood-2025-3546

Abstract Adult T-cell leukemia-lymphoma (ATL) is a highly aggressive T cell malignancy with dismal prognosis caused by the human T-cell leuk...

GB3226, a novel, orally active, first-in-class small molecule inhibitor of ENL-yeats and FLT3 kinase for the treatment of Relapsed/Refractory Acute Myeloid Leukemia

Louis Renzetti, Stacia Kargman, Joseph Vacca et al. Nov 03, 2025 pp. 6106-6106 10.1182/blood-2025-6106

Abstract Background: The YEATS domain of ENL is an epigenetic reader protein that binds to acetylation sites on histones and exerts transcri...

Disease characteristics and outcomes of acute lymphoblastic leukemia (ALL) in adults with central nervous system (CNS) involvement

Michal Bar-Natan, Sarra Yekta, Justin Kaner et al. Nov 03, 2025 pp. 1557-1557 10.1182/blood-2025-1557

Abstract Background: Despite major advances in the treatment of ALL and incorporation of CNS prophylaxis, the risk factors for and outcomes...

Extrafollicular B cell expansion in COVID-19 patients with prothrombotic antibodies linked to inflammatory and Th1 signatures

Nathan Witman, Mei Yu, Yuqi Zhang et al. Nov 03, 2025 pp. 1232-1232 10.1182/blood-2025-1232

Abstract Despite the availability of effective vaccines, COVID-19 continues to pose a global health challenge. Severe acute COVID-19 cases a...

Prediction and prevalence of non-anemic iron deficiency (NAID) in early pregnancy

Sarah Detlefs, Chirag Patel, Jacquelyn Powers et al. Nov 03, 2025 pp. 1125-1125 10.1182/blood-2025-1125

Abstract Background: Non-anemic iron deficiency (NAID) is estimated to affect up to 42% of early pregnancies and is associated with adverse...

Cardiovascular disease risk assessment in Japanese adults with hemophilia: Interim results of a multicenter study

Yushi Chikasawa, Hisanori Kosuge, Azusa Nagao et al. Nov 03, 2025 pp. 4843-4843 10.1182/blood-2025-4843

Abstract Background Although patients with hemophilia have historically been considered at low risk for cardiovascular disease (CVD), recent...

Proteomic profiling of amyloid deposits in advanced systemic light-chain (AL) amyloidosis: Insights into clonal light chains, chaperone proteins, and cardiac involvement

Piaorong Zeng, Yangqiu Li, Yikai Zhang et al. Nov 03, 2025 pp. 2189-2189 10.1182/blood-2025-2189

Abstract Background: Systemic light-chain (AL) amyloidosis with advanced cardiac involvement is associated with markedly reduced survival. T...

Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated Results from the Phase 1/2 SYRUS study

Ibrahim Aldoss, Pere Barba, Pau Montesinos et al. Nov 03, 2025 pp. 3345-3345 10.1182/blood-2025-3345

Abstract Introduction: Management of R/R ALL remains challenging. While CD19-targeted therapies haveshown compelling clinical activity, exist...

Improved outcomes in 17,908 acute myeloid leukemia patients across last three decades: Results from the multinational pethema registry

Jorge Labrador, David Martinez-Cuadron, Cristina Gil et al. Nov 03, 2025 pp. 40-40 10.1182/blood-2025-40

Abstract Background: The therapeutic landscape of acute myeloid leukemia (AML) has evolved substantially over the past three decades. While...

Risk of second primary malignancies and leukemic transformation in patients with Philadelphia chromosome-negative myeloproliferative neoplasms: A population-level US retrospective cohort study

Debolina Pramanik, Yanwen Chen, Shramana Sarkar et al. Nov 03, 2025 pp. 3790-3790 10.1182/blood-2025-3790

Abstract INTRODUCTION There is sparse population-level data on the risk of second primary malignancy (SPM) and leukemic transformation in Phi...

Phenotypic characterization of chimeric ilt receptor natural killer (CIR-NK) cells targeting HLA-G+ tumors for allogeneic donor identification

MyLinh Duong, Jihyun Park, Raphael Ognar et al. Nov 03, 2025 pp. 5917-5917 10.1182/blood-2025-5917

Abstract Introduction HLA-G is an immunosuppressing MHC-IB that acts through ILT2 and ILT4 receptors to block allogeneic...

Dysregulation of NF-kb and p73 signal axes in chronic lymphocytic leukemia with gain-of-function mutated p53

Samon Benrashid, Britten Gordon, Andrew Mitchell et al. Nov 03, 2025 pp. 7405-7405 10.1182/blood-2025-7405

Abstract Background: Genetic alterations in TP53 are common in CLL (10% at diagnosis, 40% at relapse) and are thought to be the foremost mar...

Identifying epigenetic vulnerabilities for treatment of HMA refractory myeloid leukemia

Alan Shih, Richard Koche, Michael Waarts et al. Nov 03, 2025 pp. 3269-3269 10.1182/blood-2025-3269

Abstract Introduction Epigenetic mutations (e.g. TETE2, ASXL1, DNMT3A) are a frequently occurring class of mutations in Acute Myeloid Leukemi...

Risk of second primary hematological malignancy post chimeric antigen receptor T-cell therapy in diffuse large B-cell lymphoma: Propensity-matched analysis using trinetx database

Juhi Chovatiya, Amna Bint I Munir, Nency Ganatra et al. Nov 03, 2025 pp. 1951-1951 10.1182/blood-2025-1951

Abstract Background: Chimeric antigen receptor T-cell (CAR-T) therapy has improved the outcomes for patients with relapsed or refractory dif...

Continuous‑infusion cytarabine for leukoreduction in hyperleukocytic AML: A single‑center retrospective study

Johnathan Fraebel, Aaron Pathak, Purnima Sravanti Teegavarapu et al. Nov 03, 2025 pp. 6992-6992 10.1182/blood-2025-6992

Abstract Background: Hyperleukocytosis (WBC > 50 × 10⁹/L) in acute myeloid leukemia (AML) is a medical emergency associated with a ≥2...

Pericapsular nerve block and ablation as a novel pain modifying strategy in sickle cell patients wiht refractory hip pain due to avascular necrosis

Benjamin Morales Castelan, Shenise Gilyard, Amie Patel et al. Nov 03, 2025 pp. 6217-6217 10.1182/blood-2025-6217

Abstract Introduction: People living with sickle cell disease (SCD) have an average of four to six pain crisis episodes requiring hospitaliz...

Registration and characterization of patients with Glucose-6-Phosphate Dehydrogenase Deficiency in Spain: A  real-world study of the Spanish Erythropathology Group (GEE)

María Menor Gómez, María Sánchez Villalobos, Eduardo Salido Fiérrez et al. Nov 03, 2025 pp. 4723-4723 10.1182/blood-2025-4723

Abstract Introduction: Enzymatic deficiencies of red blood cells, or erythroenzymopathies, are rare genetic disorders that affect intraeryth...

A single center review of secondary hemophagocytic lymphohistiocytosis treatment and outcomes.

Brenda Castillo, Aaron Boothby, Sarah Monsell et al. Nov 03, 2025 pp. 6548-6548 10.1182/blood-2025-6548

Abstract Authors: Brenda S. Castillo, MD, Stephen Njau, MD, Sarah Monsell, Aaron Boothby, MD, Paul C. Hendrie, MD, PhD, Prakash Vishnu, MD,...

Chronic lymphocytic leukemia mortality among u.S adults aged ≥65: A 56-year trend analysis and demographic disparities

Haseeb Tareen, Saif Ali Khan, Allah Dad et al. Nov 03, 2025 pp. 8031-8031 10.1182/blood-2025-8031

Abstract Introduction: Chronic lymphocytic leukemia (CLL) is the most prevalent form of leukemia among older adults, with mortality trends i...

Clinical significance of RAS-MAPK pathway mutations in Acute Myeloid Leukemia: Insights from a retrospective cohort

Moath Albliwi, Emily Zabor, John Hanna et al. Nov 03, 2025 pp. 5185-5185 10.1182/blood-2025-5185

Abstract Background Dysregulation of the RAS-MAPK signaling pathway is among the most common molecular abnormalities observed in neoplastic...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page